Sana Haider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sana Haider has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
W. Chua
School of Medicine, Western Sydney University, Campbelltown, Australia
2 shared publicationsWei Chua
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
2 shared publicationsA. Cooper
Department of Medical Oncology, Liverpool Hospital, Liverpool; Ingham Institute for Applied Medical Research, Liverpool; School of Medicine, Western Sydney University, Sydney
1 shared publicationA. Pal
Department of Medical Oncology, Liverpool Hospital, Liverpool; Department of Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, Australia
1 shared publicationA. Roohullah
Department of Medical Oncology, Liverpool Hospital, Liverpool; Ingham Institute for Applied Medical Research, Liverpool; School of Medicine, Western Sydney University, Sydney; Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown
1 shared publication- B. Balakrishnar
Department of Medical Oncology, Liverpool Hospital, Liverpool, Australia
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 29, 101559
Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis
- 2 December 2025
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 29, 101559
Open AccessSafety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis
- Open Access
- 21 November 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (11) , e007885
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use
Immune checkpoint inhibitors (ICIs) have transformed the landscape of solid cancer management. These drugs carry a risk of novel side effects, which have become known as immune-related adverse events (irAEs). Traditionally, irAEs have been managed empirically with corticosteroids. A subset of these may be steroid refractory and as more evidence emerges about their distinct pathogeneses, a more tailored approach is required. Here, we report the use of a Janus kinase (JAK) inhibitor, baricitinib, in a patient with chronic inflammatory demyelinating polyneuropathy secondary to ICI use. We also review the current literature with regards to the use of these inhibitors in the management of irAEs. Modulation of the JAK pathway warrants further investigation in the targeted management of irAEs.
- 21 November 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (11) , e007885
Open AccessNovel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use
Immune checkpoint inhibitors (ICIs) have transformed the landscape of solid cancer management. These drugs carry a risk of novel side effects, which have become known as immune-related adverse events (irAEs). Traditionally, irAEs have been managed empirically with corticosteroids. A subset of these may be steroid refractory and as more evidence emerges about their distinct pathogeneses, a more tailored approach is required. Here, we report the use of a Janus kinase (JAK) inhibitor, baricitinib, in a patient with chronic inflammatory demyelinating polyneuropathy secondary to ICI use. We also review the current literature with regards to the use of these inhibitors in the management of irAEs. Modulation of the JAK pathway warrants further investigation in the targeted management of irAEs.
- 11 December 2020
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (11) , 1891-1896
Polypharmacy and the use of low or limited value medications in advanced cancer
Background: Patients with advanced malignancy are often on medications for co‐morbidities, including those for primary or secondary prevention. The benefit from these medications can be limited and may result in adverse effects, interact with medications used for the malignancy or associated symptoms, increase pill burden and reduce quality of life.Aims: To evaluate the proportion of patients with advanced malignancy that were continued on low or limited value medications and identify the factors associated with this. We also sought to determine how prevalent polypharmacy was within this group of patients and the factors associated with this.Methods: A retrospective chart review was conducted of patients with incurable malignancy admitted under medical oncology at Liverpool Hospital over a 90‐day period. Demographic variables, co‐morbidities, disease related parameters and medications were reviewed. Criteria were established to identify low or limited value medications.Results: Seventy‐eight patients were identified between September and December 2018. Thirty‐day mortality was 33%. Sixty‐five percent of the cohort was on five or more medications and 24% on 10 or more. One low or limited value medication was reported in 36% and 20% were on two or more. Age ≤60 years was associated with a risk of being on at least one unnecessary medication. Patients with fewer co‐morbidities and those in their last 3 months of life were significantly less likely to have polypharmacy. Nine percent of the cohort was on three or more antihypertensives and 6% of patients were on three or more oral hypoglycaemics.Conclusion: Polypharmacy and continued prescribing of low or limited value medications was identified in a high proportion of patients. Further studies are needed to assess the impact of continuing these medications, as well as investigation of patient and physician attitudes towards de‐escalation.
- 11 December 2020
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (11) , 1891-1896
Polypharmacy and the use of low or limited value medications in advanced cancer
Background: Patients with advanced malignancy are often on medications for co‐morbidities, including those for primary or secondary prevention. The benefit from these medications can be limited and may result in adverse effects, interact with medications used for the malignancy or associated symptoms, increase pill burden and reduce quality of life.Aims: To evaluate the proportion of patients with advanced malignancy that were continued on low or limited value medications and identify the factors associated with this. We also sought to determine how prevalent polypharmacy was within this group of patients and the factors associated with this.Methods: A retrospective chart review was conducted of patients with incurable malignancy admitted under medical oncology at Liverpool Hospital over a 90‐day period. Demographic variables, co‐morbidities, disease related parameters and medications were reviewed. Criteria were established to identify low or limited value medications.Results: Seventy‐eight patients were identified between September and December 2018. Thirty‐day mortality was 33%. Sixty‐five percent of the cohort was on five or more medications and 24% on 10 or more. One low or limited value medication was reported in 36% and 20% were on two or more. Age ≤60 years was associated with a risk of being on at least one unnecessary medication. Patients with fewer co‐morbidities and those in their last 3 months of life were significantly less likely to have polypharmacy. Nine percent of the cohort was on three or more antihypertensives and 6% of patients were on three or more oral hypoglycaemics.Conclusion: Polypharmacy and continued prescribing of low or limited value medications was identified in a high proportion of patients. Further studies are needed to assess the impact of continuing these medications, as well as investigation of patient and physician attitudes towards de‐escalation.